Dapagliflozin/saxagliptin
Dapagliflozin/saxagliptin, sold under the brand name Qtern, is a fixed-dose combination anti-diabetic medication used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is a combination of dapagliflozin and saxagliptin. It is taken by mouth.

The most common side effects include upper respiratory tract infection (such as nose and throat infections) and, when used with a sulphonylurea, hypoglycaemia (low blood glucose levels).

Dapagliflozin/saxagliptin was approved for medical use in the European Union in July 2016, and in the United States in February 2017.
Q1779868
fixed-dose combination
Concept
Q575062
anti-diabetic medication
Concept
Q1100933
glycemic control
Concept
Q3025883
type 2 diabetes
Concept
Q409898
dapagliflozin
Concept
Q3121121
saxagliptin
Concept
Q104843718
Dapagliflozin/saxagliptin
UNK
Q104843718
Dapagliflozin/saxagliptin
UNK
2016-07-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
July 2016
DATE
2017-02-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
February 2017
DATE
+2^^http://www.w3.org/2001/XMLSchema#decimal
2
NUMBER
use